TERT Promoter Mutations Common in Melanoma

A recent study has confirmed that TERT promoter mutations are common genetic mutations in cutaneous melanoma, mutations that may be linked with poor prognosis.


The PD-1 inhibitor nivolumab increased progression-free and overall survival compared with chemo in patients with previously untreated metastatic melanoma.

Patients with untreated metastatic melanoma had a significant improvement in overall survival when treated with a BRAF/MEK inhibitor combo.

The FDA has granted nivolumab (Opdivo) accelerated approval for the treatment of patients with unresectable or metastatic melanoma who no longer respond to other treatments.

Researchers have identified two new panRAF inhibitors that could be used to treat patients with BRAF- or NRAS-mutant melanoma, and those who have developed resistance to BRAF inhibitors.

Using whole-exome sequencing, researchers were able to define the genetic basis for deriving benefit from treatments that block CTLA-4 in melanoma.

The addition of sargramostim to the anti-CTLA-4 ipilimumab resulted in a significant improvement in overall survival in patients with metastatic melanoma.

In this interview we discuss a patient who experienced regression of BRAF-inhibitor-induced eruptive melanocytic nevi following concomitant addition of a MEK inhibitor.


Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.